US2003170216A1PendingUtilityA1

SYN3 compositions and methods

49
Assignee: SCHERING PLOUGH CORPPriority: Dec 20, 2001Filed: Dec 20, 2002Published: Sep 11, 2003
Est. expiryDec 20, 2021(expired)· nominal 20-yr term from priority
Inventors:Peter M. IhnatLeonore C. Witchey-LakshmananVarda SandweissSydney Ugwu
A61P 43/00A61P 35/00A61P 13/10C12N 15/86C07J 41/0061A61K 31/704A61K 47/12A61K 31/7028A61K 48/0008A61K 9/19A61K 31/70C12N 2710/10343A61K 38/212A61K 47/26A61K 48/00A61K 9/0019A61K 47/10A61K 47/18C12N 2710/10351
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are aqueous and nonaqueous solution formulations containing agents that are useful for treating cancer.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A pharmaceutical composition comprising SYN3 in combination with a pharmaceutically acceptable carrier.  
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein said composition further comprises at least one pharmaceutically acceptable solubilizer.  
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein said composition is lyophilized.  
     
     
         4 . The lyophilized pharmaceutical composition of  claim 3 , wherein said composition further comprises at least one pharmaceutically acceptable bulking agent.  
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein said composition further comprises an expression vector comprising a foreign DNA sequence inserted into the vector.  
     
     
         6 . The pharmaceutical composition of  claim 5 , wherein said composition further comprises at least one pharmaceutically acceptable solubilizer.  
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein said pharmaceutically acceptable carrier is a nonaqueous carrier.  
     
     
         8 . The pharmaceutical composition of  claim 7 , wherein said composition further comprises at least one pharmaceutically acceptable solubilizer.  
     
     
         9 . The pharmaceutical composition of  claim 7 , wherein said composition further comprises an expression vector comprising a foreign DNA sequence inserted into the vector.  
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein said composition further comprises at least one pharmaceutically acceptable solubilizer.  
     
     
         11 . The pharmaceutical composition of  claim 1 , wherein said pharmaceutically acceptable carrier is an aqueous carrier.  
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein said composition further comprises at least one pharmaceutically acceptable solubilizer.  
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein said composition further comprises at least one pharmaceutically acceptable bulking agent.  
     
     
         14 . The pharmaceutical composition of  claim 13 , wherein said composition further comprises at least one pharmaceutically acceptable buffering agent.  
     
     
         15 . The pharmaceutical composition of  claim 11 , wherein said composition further comprises an expression vector comprising a foreign DNA sequence inserted into the vector.  
     
     
         16 . The pharmaceutical composition of  claim 15 , wherein said composition further comprises at least one pharmaceutically acceptable solubilizer.  
     
     
         17 . The pharmaceutical composition of  claim 16 , wherein said composition further comprises at least one pharmaceutically acceptable bulking agent.  
     
     
         18 . The pharmaceutical composition of  claim 17 , wherein said composition further comprises at least one pharmaceutically acceptable buffering agent.  
     
     
         19 . A method of treating a disease in a mammal, said method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising SYN3 in combination with a pharmaceutically acceptable carrier.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.